开发一种原型的,可在现场使用的诊断工具,用于检测牛群中菌诱导的グラム阳性乳腺炎
Anna Dobrut1, Jakub Skibiński2,3, Adrian Bekier4
1Department of Molecular Medical Microbiology, Chair of Microbiology, Jagiellonian University Medical College, Krakow, Poland. anna.dobrut@uj.edu.pl.
BMC veterinary research
|May 2, 2024
概括
使用延长因子Tu的新侧流免疫试验 (LFIA) 显示出用于诊断牛乳腺炎的前景. 该测试旨在识别特定的细菌病原体,克服当前体细胞计数方法的局限性.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 免疫诊断 免疫诊断 免疫诊断 免疫诊断
- 细菌学 细菌学是一门学科.
背景情况:
- 牛乳炎在乳制品行业造成重大经济损失.
- 目前的诊断依赖于体细胞计数 (SCC),它无法识别致病原体.
- 这种诊断差距阻碍了针对性的抗微生物治疗,并导致了抗微生物药物耐药性.
研究的目的:
- 开发一种侧流免疫试验 (LFIA) 用于识别导致牛乳腺炎的流行格拉姆阳性.
- 使用延长因子Tu (EF-Tu) 作为LFIA开发的目标.
- 为了解决识别病原体的诊断测试的需要,与SCC不同.
主要方法:
- 开发一个侧流免疫试验 (LFIA).
- 针对病原体检测的延长因子Tu (EF-Tu) 的准.
- 测试LFIA变体的Streptococcus uberis和一个更广泛的格拉姆阳性虫小组.
主要成果:
- 对S. uberis的测定达到89.02%的特异性,43.59%的灵敏性和80.3%的准确性.
- 对格拉姆阳性菌的测定显示了95.59%的特异性,43.28%的灵敏性和78.33%的准确性.
- 延长因子Tu (EF-Tu) 证明是LFIA发展的可行目标.
结论:
- 延长因子Tu (EF-Tu) 是开发牛乳腺炎LFIA测试的有希望的目标.
- 开发的LFIA显示了通过识别致病原体来改善诊断的潜力.
- 建议进行进一步的评估和优化,以提高测试参数,填补乳腺炎诊断中的关键差距.
相关概念视频
Rapid Identification of Pathogens
MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...
Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...


